Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual MeetingGlobeNewsWire • 04/15/25
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR MeetingGlobeNewsWire • 03/25/25
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/07/25
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic OutlookGlobeNewsWire • 03/06/25
Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should KnowZacks Investment Research • 02/27/25
Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock?Zacks Investment Research • 02/11/25
Foghorn Therapeutics (FHTX) Loses -23.05% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 01/15/25
Foghorn Therapeutics (FHTX) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 01/09/25
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic PrioritiesGlobeNewsWire • 12/16/24
After Plunging -30.17% in 4 Weeks, Here's Why the Trend Might Reverse for Foghorn Therapeutics (FHTX)Zacks Investment Research • 12/12/24
Wall Street Analysts See a 104.08% Upside in Foghorn Therapeutics (FHTX): Can the Stock Really Move This High?Zacks Investment Research • 11/25/24
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/04/24
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate UpdateGlobeNewsWire • 11/04/24
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid TumorsGlobeNewsWire • 10/10/24
Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength?Zacks Investment Research • 09/16/24
Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business OfficerGlobeNewsWire • 09/03/24
Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 81.16%: Read This Before Placing a BetZacks Investment Research • 09/02/24
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in SeptemberGlobeNewsWire • 08/28/24
Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 121.77%: Here's is How to TradeZacks Investment Research • 08/16/24
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/08/24
Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate UpdateGlobeNewsWire • 08/08/24
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance PipelineGlobeNewsWire • 05/22/24